Is it safe to prescribe clomiphene citrate without ultrasound monitoring facilities?
Coughlan, C Fitzgerald, J Milne, P Wingfield, M
Coughlan, C
Fitzgerald, J
Milne, P
Wingfield, M
Advisors
Editors
Other Contributors
Date
2010-05
Date Submitted
Keywords
Other Subjects
Subject Mesh
Clomiphene
Female
Fertility Agents, Female
Humans
Pregnancy
Retrospective Studies
Superovulation
Ultrasonography
Female
Fertility Agents, Female
Humans
Pregnancy
Retrospective Studies
Superovulation
Ultrasonography
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
The majority of triplet and higher order multiple pregnancies now result from ovulation induction/superovulation rather than in vitro fertilisation. However, clomiphene citrate is still widely prescribed by gynaecologists and general practitioners who do not have access to ultrasound monitoring. The objective of our study was to determine the prevalence of multifollicular development with different doses of clomiphene citrate. A retrospective review of transvaginal ultrasound monitoring of 425 cycles in 182 women receiving clomiphene citrate from January 2002 to December 2003, was studied. Three or more follicles of >or= 14 mm were identified in 58 cycles (14%). Patients received 50 mg of clomiphene citrate in 52 of these 58 cycles and 25 mg in the remaining six. One patient was noted to have developed five follicles and 10 patients developed four follicles. One patient developed six follicles, despite receiving only 25 mg clomiphene citrate daily. It was concluded that a significant number of women (14%) developed three or more follicles, despite receiving low doses of clomiphene citrate.
Language
en
ISSN
1364-6893
eISSN
ISBN
DOI
10.3109/01443611003646280
PMID
20455725
PMCID
Sponsorships
Funding Sources
Funding Amounts
Grant Identifiers
Methodology
Duration
Ethical Approval
N/A